WO2010002160A2 - 돼지의 알파에스 1 카제인 유전자, 그 프로모터 및 그의 용도 - Google Patents
돼지의 알파에스 1 카제인 유전자, 그 프로모터 및 그의 용도 Download PDFInfo
- Publication number
- WO2010002160A2 WO2010002160A2 PCT/KR2009/003516 KR2009003516W WO2010002160A2 WO 2010002160 A2 WO2010002160 A2 WO 2010002160A2 KR 2009003516 W KR2009003516 W KR 2009003516W WO 2010002160 A2 WO2010002160 A2 WO 2010002160A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- vector
- casein
- expression vector
- gene
- seq
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 142
- 108050000244 Alpha-s1 casein Proteins 0.000 title claims abstract description 63
- 102000009366 Alpha-s1 casein Human genes 0.000 title claims description 54
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 46
- 239000013604 expression vector Substances 0.000 claims abstract description 44
- 241001465754 Metazoa Species 0.000 claims abstract description 42
- 235000013336 milk Nutrition 0.000 claims abstract description 19
- 239000008267 milk Substances 0.000 claims abstract description 19
- 210000004080 milk Anatomy 0.000 claims abstract description 19
- 238000004519 manufacturing process Methods 0.000 claims abstract description 18
- 239000013598 vector Substances 0.000 claims description 163
- 239000002773 nucleotide Substances 0.000 claims description 64
- 125000003729 nucleotide group Chemical group 0.000 claims description 64
- 108010076119 Caseins Proteins 0.000 claims description 43
- 241000282898 Sus scrofa Species 0.000 claims description 43
- 235000018102 proteins Nutrition 0.000 claims description 26
- 230000009261 transgenic effect Effects 0.000 claims description 17
- 241000282887 Suidae Species 0.000 claims description 16
- 241000699670 Mus sp. Species 0.000 claims description 11
- 238000000520 microinjection Methods 0.000 claims description 11
- 241000699666 Mus <mouse, genus> Species 0.000 claims description 9
- 239000003550 marker Substances 0.000 claims description 9
- 241000700605 Viruses Species 0.000 claims description 8
- 238000002347 injection Methods 0.000 claims description 8
- 239000007924 injection Substances 0.000 claims description 8
- 239000012212 insulator Substances 0.000 claims description 8
- 210000001082 somatic cell Anatomy 0.000 claims description 8
- 241000283707 Capra Species 0.000 claims description 7
- 238000012546 transfer Methods 0.000 claims description 7
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 6
- 238000003776 cleavage reaction Methods 0.000 claims description 6
- 210000003101 oviduct Anatomy 0.000 claims description 6
- 230000007017 scission Effects 0.000 claims description 6
- 241000283690 Bos taurus Species 0.000 claims description 4
- 241000283923 Marmota monax Species 0.000 claims description 4
- 230000001124 posttranscriptional effect Effects 0.000 claims description 4
- 230000001105 regulatory effect Effects 0.000 claims description 4
- 101000987586 Homo sapiens Eosinophil peroxidase Proteins 0.000 claims description 3
- 241001494479 Pecora Species 0.000 claims description 3
- 102000044890 human EPO Human genes 0.000 claims description 3
- 102000003951 Erythropoietin Human genes 0.000 claims description 2
- 108090000394 Erythropoietin Proteins 0.000 claims description 2
- 101000920686 Homo sapiens Erythropoietin Proteins 0.000 claims description 2
- 108091036066 Three prime untranslated region Proteins 0.000 claims description 2
- 229940105423 erythropoietin Drugs 0.000 claims description 2
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims description 2
- 235000020256 human milk Nutrition 0.000 claims 1
- 210000004251 human milk Anatomy 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 40
- 108020004414 DNA Proteins 0.000 description 31
- 238000000034 method Methods 0.000 description 30
- 102000011632 Caseins Human genes 0.000 description 25
- 101000741052 Sus scrofa Alpha-S1-casein Proteins 0.000 description 21
- 235000013601 eggs Nutrition 0.000 description 20
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 18
- 238000006243 chemical reaction Methods 0.000 description 18
- 239000005018 casein Substances 0.000 description 17
- 235000021240 caseins Nutrition 0.000 description 17
- 238000004925 denaturation Methods 0.000 description 17
- 230000036425 denaturation Effects 0.000 description 17
- 108091008146 restriction endonucleases Proteins 0.000 description 17
- 238000012408 PCR amplification Methods 0.000 description 16
- 229930193140 Neomycin Natural products 0.000 description 15
- 229960004927 neomycin Drugs 0.000 description 15
- 239000000523 sample Substances 0.000 description 13
- 238000012163 sequencing technique Methods 0.000 description 12
- 239000002609 medium Substances 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 238000010276 construction Methods 0.000 description 9
- 241000700159 Rattus Species 0.000 description 8
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 8
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 8
- 230000035772 mutation Effects 0.000 description 8
- 210000004940 nucleus Anatomy 0.000 description 8
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 8
- 208000009889 Herpes Simplex Diseases 0.000 description 7
- 108091000080 Phosphotransferase Proteins 0.000 description 7
- 102000020233 phosphotransferase Human genes 0.000 description 7
- 108020005345 3' Untranslated Regions Proteins 0.000 description 6
- 108020003589 5' Untranslated Regions Proteins 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 6
- 241001045988 Neogene Species 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 238000004113 cell culture Methods 0.000 description 6
- 238000003780 insertion Methods 0.000 description 6
- 230000037431 insertion Effects 0.000 description 6
- 210000005075 mammary gland Anatomy 0.000 description 6
- 101150091879 neo gene Proteins 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 5
- 102000011755 Phosphoglycerate Kinase Human genes 0.000 description 5
- 108091081024 Start codon Proteins 0.000 description 5
- 101001099217 Thermotoga maritima (strain ATCC 43589 / DSM 3109 / JCM 10099 / NBRC 100826 / MSB8) Triosephosphate isomerase Proteins 0.000 description 5
- 229960000723 ampicillin Drugs 0.000 description 5
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 5
- 239000012091 fetal bovine serum Substances 0.000 description 5
- 238000003753 real-time PCR Methods 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 229940104230 thymidine Drugs 0.000 description 5
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 4
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 4
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 4
- 102000004877 Insulin Human genes 0.000 description 4
- 108090001061 Insulin Proteins 0.000 description 4
- 229930182555 Penicillin Natural products 0.000 description 4
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 4
- 238000010367 cloning Methods 0.000 description 4
- 239000013599 cloning vector Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 229940125396 insulin Drugs 0.000 description 4
- 210000001161 mammalian embryo Anatomy 0.000 description 4
- 210000004216 mammary stem cell Anatomy 0.000 description 4
- 229940049954 penicillin Drugs 0.000 description 4
- 238000010839 reverse transcription Methods 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 229960005322 streptomycin Drugs 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 108020004705 Codon Proteins 0.000 description 3
- 101100333654 Homo sapiens EPO gene Proteins 0.000 description 3
- 102100034343 Integrase Human genes 0.000 description 3
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 238000012790 confirmation Methods 0.000 description 3
- 238000005520 cutting process Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000013011 mating Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 150000007523 nucleic acids Chemical group 0.000 description 3
- 210000000287 oocyte Anatomy 0.000 description 3
- 210000001672 ovary Anatomy 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- 230000014616 translation Effects 0.000 description 3
- 235000021247 β-casein Nutrition 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 101800000414 Corticotropin Proteins 0.000 description 2
- 241000701022 Cytomegalovirus Species 0.000 description 2
- 238000001712 DNA sequencing Methods 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 102000006771 Gonadotropins Human genes 0.000 description 2
- 108010086677 Gonadotropins Proteins 0.000 description 2
- 101000897480 Homo sapiens C-C motif chemokine 2 Proteins 0.000 description 2
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 2
- 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 2
- 102000018251 Hypoxanthine Phosphoribosyltransferase Human genes 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- 102100027467 Pro-opiomelanocortin Human genes 0.000 description 2
- 102000003946 Prolactin Human genes 0.000 description 2
- 108010057464 Prolactin Proteins 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 239000006180 TBST buffer Substances 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 101150047086 arm gene Proteins 0.000 description 2
- 210000004436 artificial bacterial chromosome Anatomy 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 108010006025 bovine growth hormone Proteins 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 2
- 229960000258 corticotropin Drugs 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 210000002257 embryonic structure Anatomy 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 230000004720 fertilization Effects 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000002622 gonadotropin Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000003394 haemopoietic effect Effects 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- 238000002744 homologous recombination Methods 0.000 description 2
- 230000006801 homologous recombination Effects 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 210000000663 muscle cell Anatomy 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 229940097325 prolactin Drugs 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000001177 retroviral effect Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 238000011830 transgenic mouse model Methods 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 108700026220 vif Genes Proteins 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 235000021249 α-casein Nutrition 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 1
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 1
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000282552 Chlorocebus aethiops Species 0.000 description 1
- 102000011022 Chorionic Gonadotropin Human genes 0.000 description 1
- 108010062540 Chorionic Gonadotropin Proteins 0.000 description 1
- 241001429175 Colitis phage Species 0.000 description 1
- 235000005956 Cosmos caudatus Nutrition 0.000 description 1
- 108010080611 Cytosine Deaminase Proteins 0.000 description 1
- 102000004594 DNA Polymerase I Human genes 0.000 description 1
- 108010017826 DNA Polymerase I Proteins 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 230000007018 DNA scission Effects 0.000 description 1
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 1
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 108010053187 Diphtheria Toxin Proteins 0.000 description 1
- 101100497384 Drosophila melanogaster CASK gene Proteins 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000740205 Homo sapiens Sal-like protein 1 Proteins 0.000 description 1
- 101150003028 Hprt1 gene Proteins 0.000 description 1
- 108010003272 Hyaluronate lyase Proteins 0.000 description 1
- 102000001974 Hyaluronidases Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 241000713333 Mouse mammary tumor virus Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 101800000989 Oxytocin Proteins 0.000 description 1
- XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 description 1
- 102100031951 Oxytocin-neurophysin 1 Human genes 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 238000012181 QIAquick gel extraction kit Methods 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 230000021839 RNA stabilization Effects 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 101100272807 Rattus norvegicus Btg2 gene Proteins 0.000 description 1
- 206010038997 Retroviral infections Diseases 0.000 description 1
- 102100037204 Sal-like protein 1 Human genes 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 101150003725 TK gene Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 108091023045 Untranslated Region Proteins 0.000 description 1
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 1
- 102000002852 Vasopressins Human genes 0.000 description 1
- 108010004977 Vasopressins Proteins 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 229960002478 aldosterone Drugs 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 210000002459 blastocyst Anatomy 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- ARQRPTNYUOLOGH-UHFFFAOYSA-N chcl3 chloroform Chemical compound ClC(Cl)Cl.ClC(Cl)Cl ARQRPTNYUOLOGH-UHFFFAOYSA-N 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 229940084986 human chorionic gonadotropin Drugs 0.000 description 1
- 229960002773 hyaluronidase Drugs 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000009027 insemination Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 101150070593 lox gene Proteins 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 210000004681 ovum Anatomy 0.000 description 1
- XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 1
- 229960001723 oxytocin Drugs 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- YFDSDPIBEUFTMI-UHFFFAOYSA-N tribromoethanol Chemical compound OCC(Br)(Br)Br YFDSDPIBEUFTMI-UHFFFAOYSA-N 0.000 description 1
- 229950004616 tribromoethanol Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 239000003656 tris buffered saline Substances 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 210000001177 vas deferen Anatomy 0.000 description 1
- 229960003726 vasopressin Drugs 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4732—Casein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/505—Erythropoietin [EPO]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/20—Animal model comprising regulated expression system
- A01K2217/206—Animal model comprising tissue-specific expression system, e.g. tissue specific expression of transgene, of Cre recombinase
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/108—Swine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/01—Animal expressing industrially exogenous proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/48—Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE
Definitions
- the present invention relates to a pig alpha 1 casein gene, a pig alpha 1 casein gene promoter, an expression vector comprising the same, and a method for preparing a protein using the same.
- the mass production method by cell culture is mainly used.
- Korean Patent Application No. 94-12082 discloses an expression vector comprising a modified recombinant human hematopoietic hematopoietic factor (rhEPO) gene, and an animal cell line COS-7 (ATCC CRL 1651, African Green Monkey Kidney) transformed with the expression vector.
- rhEPO human hematopoietic hematopoietic factor
- COS-7 African Green Monkey Kidney
- Korean Patent No. 10-0358754 discloses a transgenic animal (Saromyi) that produces EPO in pig milk, but the promoter used here was a promoter of whey (WAP), which occupies a small portion of the milk component. .
- the present inventors In order to develop a mammary gland specific promoter expressing a protein of interest in milk with high efficiency, the present inventors have identified the alpha s 1 casein gene and the nucleotide sequence for the promoter and completed the present invention.
- the present invention provides a pig alpha 1 casein gene and its promoter, and to provide a method for mass production of the protein of interest using the same.
- the present invention provides swine alpha 1 casein gene.
- Porcine alpha 1 casein gene of the present invention specifically comprises a nucleotide sequence of SEQ ID NO: 1 including a promoter, and the 3 'untranslated region (UTR) region.
- the present invention also provides a promoter of SEQ ID NO: 2 corresponding to the nucleotide sequence of 1 to 9300 of SEQ ID NO: 1, wherein the promoter is located on the 5 'side of the structural gene to regulate the expression of the structural gene.
- Porcine alpha 1 casein gene, or promoter of the present invention is one or more disruptions, deletions, insertions, points, substitutions in the nucleotide sequence of SEQ ID NO: 1 or SEQ ID NO: 2 .
- Nonsense, misinse, polymorphism, rearranged mutations (functional equivalent) can be one of the selected.
- the present invention also provides an expression vector comprising all or part of the promoter of SEQ ID NO.
- the expression vector of the present invention comprises the nucleotide sequence of SEQ ID NO: 3 or SEQ ID NO: 4.
- the base sequence of SEQ ID NO: 2, SEQ ID NO: 3, or SEQ ID NO: 4 is inserted into a vector to serve as a promoter, and the sequence is called a promoter sequence or porcine alpha S1 casein gene promoter sequence.
- the term 'pig alpha S 1 casein gene promoter' used in the present invention means a promoter derived from a pig alpha S 1 casein gene.
- SEQ ID NO: 3 corresponds to the base sequence from 3568 th to 9037 th and 4321 th to 9300 th of the whole genome sequence of swine alpha 1 casein gene of SEQ ID NO: 1, and in general, exon 1 It includes an area.
- the expression vector of the present invention is a regulator at the appropriate position, if necessary, that is, another promoter, enhancer, selective marker, 5'-UTR (untranslated region), 3'-UTR, polyade
- a polyadenylation signal By further including a polyadenylation signal, a ribosomal binding sequence, a sequence that can be inserted into a specific region of the genome, an intron, or a woodchuck hepatitus virus posttranscriptional regulatory element (WPRE), it is easy to construct a transformed cell line. In addition, it is possible to maximize the amount of protein expression and stability of expression.
- the selective marker gene uses a neomycin-resistant gene and the like, and may be used by cleaving a corresponding portion from a commercially available vector.
- Neomycin resistance gene is G418 (2R, 3S, 4R, 5R, 6S) -5-amino-6-[(1R, 2S, 3S, 4R, 6S) -4,6-diamino-3- used for cell line construction.
- [(2R, 3R, 4R, 5R) -3,5-dihydroxy-5-methyl-4-methylaminooxan-2-yl] oxy-2-hydroxycyclohexyl] oxy-2- (1-hydroxyethyl) oxane-3,4- diol) is a gene that is resistant to reagents, and can serve as an efficient selective marker gene when constructing animal cell lines expressing proteins under promoter control.
- Insulators help to influence the regulators near the promoter and help position-independent expression.
- the insulator can stably express the protein under the promoter's control. Can be used after cutting.
- WPRE is a regulator that can contribute to the stabilization of mRNA to increase the amount of protein synthesis, and allows the expression of a large amount of protein under the control of a promoter. WPRE may also be cleaved from commercially available vectors.
- the expression vector of the present invention further comprises SEQ ID NO: 5, or SEQ ID NO: 6.
- the nucleotide sequence of SEQ ID NO: 5, or SEQ ID NO: 6 forms a 3'arm of the vector, facilitates the construction of a transformed cell line, and can maximize the expression level of the target protein and promote expression stability.
- SEQ ID NO: 5 and SEQ ID NO: 6 correspond to the nucleotide sequences of the 26344th to 30599th sequences and the 14447th to 19401th sequences, respectively, of the entire genome sequence of the swine alpha 1 casein gene of SEQ ID NO: 1.
- the vector of the present invention preferably comprises the nucleotide sequence of SEQ ID NO: 3, and the nucleotide sequence of SEQ ID NO: 5.
- the vector of the present invention has the cleavage map of FIG. 2, and the pBC1-pig ⁇ S1 casein vector was deposited in the Korea Biotechnology Research Institute Gene Bank (Daejeon, Korea) with accession number KCTC 11324BP.
- the expression vector pBC1-pig ⁇ S1 casein vector of the present invention uses the pBC1 vector as a basic skeleton, and neomycin resistance gene is fused as a selective marker gene.
- the expression vector of the present invention can further express the target protein by further comprising a base sequence encoding the target protein toward the 3 'of the promoter region nucleotide sequence.
- the protein of interest is an industrially available useful protein, for example, all proteins used as active ingredients of medicines, that is, EPO (eryth r opoietin), aldosterone, adreno-corticotropin (adreno-corticotropin), blood coagulation Blood clotting factor, gonado-tropin, insulin, insulin, prolactin, vasopressin, and the like, preferably human eryth r opoietin (hEPO).
- EPO eryth r opoietin
- aldosterone aldosterone
- adreno-corticotropin adreno-corticotropin
- blood coagulation Blood clotting factor gonado-tropin
- insulin insulin
- prolactin prolactin
- vasopressin vasopressin
- hEPO human eryth r opoietin
- the present invention provides a vector having a cleavage map of FIG. 3 as a preferred example of an expression vector including the neomycin resistance gene, insulator, WPRE, and the like, and specifically, a pBC1-pig ⁇ S1 casein + hEPO-WPRE vector.
- the gene bank was deposited with the accession number KCTC 11325BP.
- the pBC1-pig ⁇ S1 casein + hEPO-WPRE vector of the present invention uses the pBC1 vector as a backbone, and the gene encoding human EPO on the 3 'side of the promoter region of the present invention, and the WPRE on the 3' side of the human EPO gene are fused. It is.
- Expression vectors of the present invention can be prepared as a knock-in vector (knock-in vector).
- a “stigma vector” is a vector capable of inserting a desired gene into a specific gene position of a genome, and includes a sequence homologous to a specific gene to be targeted so that homologous recombination occurs.
- the stigma vector of the present invention is an alpha 1 casein targeting vector in which a nucleic acid sequence encoding a target protein is inserted into an alpha 1 casein gene on a genome.
- the stigma vector of the present invention preferably includes the nucleotide sequence of SEQ ID NO: 4, and the nucleotide sequence of SEQ ID NO: 6.
- the stigma vector of the present invention can select transformed cells using positive and / or negative selection genes as needed.
- a selection gene is used to select cells transformed with a vector, and genes conferring a selectable phenotype such as drug resistance, nutritional composition, resistance to cytotoxic agents or expression of surface proteins can be used, and positive selection genes. And negative selection genes.
- Positive selection genes are genes that enable positive selection by allowing only cells expressing selection genes to survive in an environment treated with a selection agent, such as neomycin (Neo) resistance gene and hygromycin (Hyg) resistance gene. have.
- Negative selection genes are genes that allow negative selection to select and remove cells that have undergone random insertion, the Herpes simplex virus-thymidine kinase (HSV-tk) gene, hypoxanthine phosphoribosyl Transferase (hypoxanthine phosphoribosyl transferase; Hprt) gene, cytosine deaminase gene, or Diphtheria toxin gene.
- HSV-tk Herpes simplex virus-thymidine kinase
- Hprt hypoxanthine phosphoribosyl Transferase
- cytosine deaminase gene or Diphtheria toxin gene.
- the negative selection gene is located at the 5 'end of the promoter region or at the 3' end of the 3'arm.
- Positive and negative screening genes can have separate promoters, polyAs, etc., and the promoters used are monkey virus 40 (SV40), mouse breast tumor virus (MMTV) promoters, and long terminal repeat (LTR) promoters of HIV. , Moroni virus, cytomegalovirus (CMV) promoter, Epstein Barr virus (EBV) promoter, Loews sacoma virus (RSV) promoter, or phosphoglycerate kinase (PGK) promoter.
- SV40 monkey virus 40
- MMTV mouse breast tumor virus
- LTR long terminal repeat
- Moroni virus cytomegalovirus
- CMV cytomegalovirus
- EBV Epstein Barr virus
- RSV Loews sacoma virus
- PGK phosphoglycerate kinase
- the nucleic acid encoding the target protein on the vector is integrated into the alpha 1 casein genomic gene of the host cell, resulting in alpha 1 casein of the host cell. It is expressed instead of a protein.
- the cleavage map of FIG. 4 is a preferred example of a stigma vector using a neomycin resistance gene as a positive selection gene and Herpes simplex virus-thymidine kinase (HSV-tk) as a negative selection gene.
- HSV-tk Herpes simplex virus-thymidine kinase
- Pig ⁇ S1 casein-hEPO knock in vector of the present invention uses a Lox A neo vector as a basic skeleton, and on the 3 'side of the promoter (meaning the Pig aS1 casein 5' arm of FIG.
- TK herpes simplex virus-thymidine kinase
- Vector production of the present invention can be prepared using genetic recombination techniques well known in the art, site-specific DNA cleavage and ligation using enzymes generally known in the art.
- the present invention also provides somatic cells of an animal transformed by introducing the expression vector of the present invention.
- Somatic cells of animals to which the vector of the present invention is introduced may be derived from pigs, etc., and may be primary, secondary or permanent cells.
- the method of introducing the vector of the present invention into the cell may use any method of introducing nucleic acid into the cell, and techniques known in the art, that is, electroporation, calcium phosphate co-precipitation precipitation, retroviral infection, microinjection, DEAE-dextran, cationic liposome, and the like can be used.
- the vector may be introduced into a linear vector form by cleaving the circular vector with an appropriate restriction enzyme or removing the plasmid.
- the promoter gene of the present invention specifically expresses the protein only in the mammary gland.
- the protein component of pig milk is 90% of casein, which is divided into alpha, beta, and gamma casein.
- alpha casein accounts for a significant portion of 70%
- alpha casein is divided into alpha 1 casein and cappacaine
- alpha 1 casein accounts for 55%, so the vector using the pig alpha S 1 casein promoter is milky.
- the present invention also provides an animal fertilized egg obtained by nuclear transfer of a nucleus of a somatic cell of an animal transformed by introducing the expression vector of the present invention into a denuclearized egg.
- Nuclear transplant refers to implanting a cell's nucleus into a cell from which the nucleus has been removed, and an individual born by implanting such a nuclear transplanted fertilized egg is transferred because the genetic material of the donor cell has been transferred to the nuclear donor cytoplasm. It will be exactly the same clone.
- the present invention also provides an animal fertilized egg into which the expression vector of the present invention is injected.
- the injection is a microinjection technique for injecting a gene as a micromanipulation technique into the male pronucleus of the conjugate at the pronuclear stage immediately after fertilization, inserting the gene into embryonic stem cells and inserting the gene into the fertilized embryo of the blastocyst.
- a method of transplanting (Stem cell insertion technique), a method of injecting a gene into a fertilized egg using a retroviral vector (Retroviral insertion technique), a gene is injected into the testis of a male to insert the gene into sperm
- the method may be modified (Sperm-mediated gene transfer technique) or the like, and a preferred example is microinjection.
- the present invention also provides a transgenic animal obtained by transplanting the animal fertilized egg of the present invention.
- Animals that can be transformed with the expression vector of the present invention are all animals that secrete milk, that is, pigs, mice, cows, sheep, goats and the like.
- the production method of the transgenic animal using the expression vector of the present invention is by a conventional method.
- fertilized eggs are collected from healthy individuals such as mice among the animals to be transformed, the expression vector of the present invention is introduced into the fertilized eggs, and the delegation mice are obtained by using the vas deferens and the like. After transplanting the fertilized egg into the embryo, it is possible to select a transformed individual from the offspring obtained from the surrogate mother.
- follicle eggs are collected from healthy individuals such as pigs and cultured in vitro maturation.
- the somatic cells into which the vector is introduced are selected and cultured.
- the nucleus is removed from the in vitro matured oocytes, donor cells are injected into this space, and the cells are cultured in vitro after fusion of donor cells and cytoplasm of the oocytes that have undergone nuclear transfer through electrofusion.
- the cloned embryos are transplanted to over-ovulation-induced poached pigs, followed by a process of selecting transformed individuals from offspring obtained from poached pigs.
- the target protein is prepared by isolating and purifying the target protein (A. Gokana, JJ Winchenn, A. Ben-Ghanem, A. Ahaded, JP Cartron, P). Lambin (1997) Chromatographic separation of recombinant human erythropoietin isoforms, Journal of chromatography, 791, 109-118).
- a separation and purification method may be used a conventional method, specifically, may be a filtration method or a chromatography method.
- the transgenic animal of the present invention prepared in this way may express the protein of interest in milk.
- the pig alpha 1 casein gene of the present invention a promoter, an expression vector and a transgenic animal using the same can be usefully used in the production of the protein of interest.
- porcine alpha 1 casein gene promoter promotes mammary specific expression of the protein of interest
- the animal transformed by the promoter of the present invention, and the expression vector using the same is made to secrete a high concentration of the target protein in milk. It can be usefully used in the production of useful proteins of significant value.
- Figure 2 shows the structure of a pBC1-pig ⁇ S1 casein vector of an embodiment of the present invention.
- Figure 3 shows the structure of the pBC1-pig ⁇ S1 casein + hEPO-WPRE vector of an embodiment of the present invention.
- Figure 4 shows the structure of a Pig ⁇ S1 casein-hEPO knock-in vector which is an embodiment of the present invention.
- FIG. 5 is a graph showing the expression results of hEPO in a cell line into which Pig ⁇ S1 casein + hEPO-WPRE vector is introduced, which is an embodiment of the present invention.
- Figure 6 shows the PCR results for selecting mice transformed with the pBC1-pig aS1 casein + hEPO-WPRE vector of an embodiment of the present invention.
- Figure 7 shows a PCR result confirming the transformation in the pups of the mouse transformed with the expression vector pBC1-pig aS1 casein + hEPO-WPRE vector of an embodiment of the present invention.
- Figure 8 shows the result of Western blot assay using the milk of the transformed mother rat an embodiment of the present invention.
- pigs have a pig genomic DNA library of promega and BAC (bacterial artificial chromosome) clones provided by the National Institute of Animal Science and Technology (National Institute of Animal Science, 564, Omokcheon-dong 77, Gwik-gu, Suwon-si, Gyeonggi-do, Korea) The sequence of the alpha s 1 casein gene (pig ⁇ S1 casein gene) was revealed.
- promega and BAC bacterial artificial chromosome
- a genomic library of pigs was screened.
- the pig genomic library used a pig genomic DNA library of promega.
- Host bacteria to be introduced into the library were prepared as follows.
- the library was serially diluted to various concentrations in SM buffer (0.1 M NaCl, 8 mM MgSO 4 , 50 mM Tris-HCl, pH 7.5, 0.01% gelatin).
- SM buffer 0.1 M NaCl, 8 mM MgSO 4 , 50 mM Tris-HCl, pH 7.5, 0.01% gelatin.
- the plate containing the solid LB medium was warmed in a 37 ° C. incubator, and the top agar was dissolved and placed in a water bath maintained at 48 ° C. 10 ⁇ l of the phage solution diluted to various concentrations and 100 ⁇ l of the host bacteria prepared above were mixed to infect the host bacteria at 37 ° C. Phage infected host bacteria were added to the top agar, shaken well, and poured onto the LB medium prepared above.
- the plates were turned upside down and incubated overnight in a 37 ° C. incubator. Plaques were formed on the medium of the plate incubated overnight, where the phage cloned the library DNA in the host bacterium and then dissolved the host bacterium, and the medium was cooled at 4 ° C. for at least 1 hour for subsequent experimental steps.
- an NC filter (Amersharm Biosciences .; UK) with serial number was prepared, and the filter was placed on the library DNA plate prepared above so as to reach from the center of the filter.
- the needle was vertically stabbed in the filter to indicate the position, and after 1 minute, the filter was carefully removed from the medium.
- Each filter was denatured (denaturation solution; 0.5 M NaOH, 1.5 M NaCl; sigma, USA), neutralization solution (1M Tris-HCl (pH 7.5), 1.5 M NaCl; sigma, USA) and 2 ⁇ It was soaked in SSC solution (0.3 M NaCl, 0.03 M Sodium citrate, sigma, USA) for 1 minute in turn and then placed in an 80 ° C. oven for 2 hours to ensure that the transferred library DNA was immobilized completely on the filter.
- SSC solution 0.3 M NaCl, 0.03 M Sodium citrate, sigma, USA
- the fixed filter is put in a sealed vinyl to prehybridization solution; 40 ml of 50% formamide, 20 ml of 20X saline-sodium phosphate-EDTA buffer, 8 ml of 50X Dehardt's solution, 1.2 ml of 100ng / ml salmon sperm DNA, 1.2 ml of 10% Sodium Dodecyl Sulfate, 0.6 ml of distilled water; sigma, USA ⁇ was added to the pre-hybridization by gently shaking for 1 hour at 68 °C. After the prehybridization reaction, 100 ng of the prepared probe factor was added, and the hybridization reaction was performed by gently shaking at 68 ° C for 18 hours.
- the filter was immersed in a 2 x SSC solution containing 0.1% SDS and washed twice with shaking at 65 ° C for 10 minutes. After washing, the filter was dried in air and autoradiography was performed. Placing positive plaques against magnetic radiographs and plates, the selected plaques were selected for SM buffer (0.1 M NaCl, 8 mM MgSO 4, 50 mM Tris-HCl (pH 7.5), 0.01% gelatin, sigam, USA) 500 Into ⁇ l 1 drop of chloroform (chloroform) was added and mixed well and stored at 4 °C. By repeating the above screening process twice, the clones having a positive response were finally obtained.
- SM buffer 0.1 M NaCl, 8 mM MgSO 4, 50 mM Tris-HCl (pH 7.5), 0.01% gelatin, sigam, USA
- PCR amplification by pairing the primers (forward primer (SEQ ID NO: 14), reverse primer (SEQ ID NO: 15)) and T7, SP6 primers (Cosmo, Korea) used to make the probe factor with the finally obtained clone
- forward primer SEQ ID NO: 14
- reverse primer SEQ ID NO: 15
- SP6 primers Cosmo, Korea
- PCR amplification resulted in a 551 bp probe with 5'UTR side and 3.7 kb in 5 'direction (SEQ ID NO: 17), and a 303 bp probe with 3'UTR side, 2.2 kb in 5' direction (SEQ ID NO: 18) and 3 'direction of 6.3 kb ( The product of SEQ ID NO: 19) was cloned into a pGEM-T vector (promega, USA) to obtain a complete sequence.
- the nucleotide sequence of alpha s 1 casein was analyzed from genomic DNA of Berksha pigs based on the pig genomic DNA library analysis and the DNA sequencing of pig alpha s 1 casein obtained from Bac clone.
- Genomic DNA was isolated from pig somatic cells distributed by Advanced Pig Research Institute (Gyeongsangnam-do, Korea) using Genomic DNA Extraction kit (cat. No. 17231) of Intron (Korea).
- Primer (SEQ ID NO: 42 ⁇ SEQ ID NO: 55) divided into 7 parts (4.6 kb, 5.7 kb, 4.9 kb, 5.3 kb, 5.3 kb, 4.7 kb, 4.4 kb) of the nucleotide sequence of alpha s1 casein 33 kb analyzed in 2) PCR amplification (PT-200, BIO-RAD, 5 minutes at 94 °C denaturation process, and then 35 cycles were carried out: after 30 seconds denaturation at 94 °C, primer binding for 30 seconds at 56 °C , Elongation reaction at 72 ° C. for 5 minutes), and then cloned into pGEM-T vector to analyze the base sequence. Sequencing was performed by Solgent (Korea).
- genomic DNA sequencing SEQ ID NO: 1
- nucleotide sequence information of porcine alpha S1 casein of Berksha species were obtained.
- the nucleotide sequence of SEQ ID NO: 1 is the entire genome sequence of the swine alpha 1 casein gene, and its size is 33248 bp.
- the structural gene region of the base sequence of SEQ ID NO: 1 is the nucleotide sequence from 7760 th to 27875 th, the start codon is the nucleotide sequence from the 9326 th to 9328 th, and the stop codon is the nucleotide sequence from the 25982 th to 25983 th 26593 base portion.
- the 5'UTR region is the nucleotide sequence from the 7760th to 7804th, and the nucleotide sequence from the 9314th to 9325th, the 3'UTR region is the nucleotide sequence from the 26594th to 26636th, and the nucleotide sequence from the 27482 to 27875th
- the polysignal region is the base sequence from 27855th to 27860th.
- Exon regions are 7760 th to 7804 th nucleotide sequence, 9314 th to 9376 th sequence, 12653 th to 12685 th sequence, 13117 th to 13137 th sequence, 13537 th to 13578 th, 14049 th To 14072 base sequences, 14780 to 14803 sequences, 16568 to 16591 sequences, 17617 to 17646 sequences, 18423 to 18446, 18533 to 18580 SEQ ID NO: 20563 th to 20604 th sequences, 22369 th to 22386 th sequences, 22868 th to 22906 th sequences, 24004 th to 24030 th sequences, 25018 th to 25041 th sequences, 25835 th
- the 25983th base sequence, the 26593th to 26636th base sequence, and the 27482th to 27875th sequence portion, and the intron region is 7 805 th to
- alpha s 1 casein amino acid sequence (SEQ ID NO: 7) was analyzed.
- the location of the probe factor and the location structure of the base sequence found by the probe factor are as shown in FIG.
- 63 / 12-ATG-48 of FIG. 1 means that ATG (start codon) following 12 nucleotide sequences of 63 base sequences of pig alpha S 1 casein 2nd exon is present and has 48 exon 2nd nucleotide sequences thereafter.
- 149 / 147-TG contains TG of 147 nucleotides out of 149 nucleotide sequences of the 17th exon of swine alpha S1 casein, followed by TG of terminating codon (TGA), and 44 / A-43 is the 18th exon of swine alpha S1 casein. It means that the A of the stop codon 44 of the base sequence is present and 43 after the exon sequence.
- Swine alpha S 1 casein sequencing and information analyzed were registered with the US National Biotechnology Information Center (EU025875).
- a neogene that can resist G418 drugs by replacing the gene with Ampicillin resistance of the pBC1 vector (Invitrogen, USA) with a neomycin resistance gene is the pEGFP-N1 vector (Clontech, USA).
- pEGFP-N1 vector (Clontech, USA).
- SEQ ID NO: 83 was obtained by amplifying the 1.9 kb PCR product (SEQ ID NO: 83) using the forward primer 5'-GCGGCCGCGCGCGTCAGGTGGCAC-3 '(SEQ ID NO: 81) and the reverse primer 5'-CGATCGGACGCTCAGTGGAACGAAAACTC-3' (SEQ ID NO: 82), This was then cloned into the pGEM T-easy vector.
- the 1.9 kb neo gene cloned into the T-vector was digested with NotI and PvuI restriction enzymes (New England Biolabs (NEB), USA) to prepare an insertion site. Also, the ampicillin-resistance gene region of the pBC1 vector was digested with NotI and PvuI restriction enzymes and removed to prepare a vector region.
- the two fragments and the vector region thus prepared were ligated to construct a pBC1 vector into which a neogene (neomycin-resistance gene) was inserted.
- a neogene neomycin-resistance gene
- a goat beta casein promoter region and 3 A cloning vector was constructed in which the genomic DNA region was substituted with the pig alpha S 1 casein promoter sequence and the 3'arm sequence, respectively.
- Two BamHI sites which are present in the alpha s1 casein promoter sequence of pigs, were not cut by the BamHI restriction enzyme through repeated point mutations as follows.
- one of the two sites was selected first to prepare a primer. After purifying the pGEM-T vector DNA containing the porcine alpha S1 casein 5 'promoter region, using 95 ng of DNA to be used as a template and a pair of point mutation primers, 95 ° C 30 seconds (1 repetition), 95 ° C 30 seconds, PCR amplification was performed at 55 ° C. for 1 minute and 72 ° C. for 8 minutes and 30 seconds (15 repetitions).
- Mutazyme TM enzyme (iNtRON Biotechnology, South Korea) was added for 1 hr to remove DNA used as a template (without point mutation) and reacted at 37 ° C for 1 hour. 10 ul of the reaction was transformed into DH10B competent cells (Invitrogen, USA) and plated in LB + Ampicillin solid medium (sigma, USA) and incubated at 37 ° C. for 20 hours. Colonies grown in LB + Ampicillin solid medium were grown in LB + Ampicillin liquid medium and purified by DNA to determine whether the BamHI site was point-mutated (GGATCC-> GGACCC) by sequencing. Using the DNA of the point mutated colony, the remaining BamHI site was also point mutated in the same manner as above. The point mutation method used here was an Intron product Site Direct Mutagenesis kit.
- a swine alpha S 1 casein promoter in the pGEM-T vector was cut with BamHI and XhoI to prepare a 8.5 kb vector.
- a nucleotide sequence portion including the 3'arm was cut into XhoI and NotI to prepare an insert (SEQ ID NO: 5) of 4.3 kb.
- SEQ ID NO: 5 Each piece was ligation to clone pGEM-T-pig ⁇ S1 casein 5 ′ + 3 ′.
- the pBC1 vector was cut with BamHI and NotI to prepare a 10 kb vector, and the pGEM-T-pig ⁇ S1 casein 5 '+ 3' vector was cut with BamHI and NotI to prepare an 9.8 kb insert. Each piece was ligated to construct a pBC1-pig ⁇ S1 casein cloning vector.
- FIG. 2 The structure of the completed pBC1-pig ⁇ S1 casein cloning vector is shown in FIG. 2.
- P ⁇ S1 casein of Figure 2 is a swine aS1 casein promoter nucleotide sequence (SEQ ID NO: 2) containing exon 1 (E1).
- Exon 1 refers to the exon is arranged first in the 5'-3 'direction of the nucleotide sequence of SEQ ID NO: 1.
- ⁇ S1-casein 3'genomic DNA of Figure 2 is the nucleotide sequence of 3'arm (SEQ ID NO: 5), including exon 18 (E18), exon 19 (E19), and intron 18 (IVS 18).
- Exon 18 and exon 19 are the 18th and 19th exons in the 5'-3 'direction of SEQ ID NO: 1, respectively, and intron 18 means the 18th intron.
- the gene of the protein of interest can be inserted into the vector.
- 2X ⁇ -globin insulator, and pBR322 are insulators and vector components derived from the pBC1 vector, and Neomycin is a neomycin resistance gene derived from the pEGFP-N1 vector (Clontech, USA).
- the pBC1-pig aS1 casein vector prepared by the above method was deposited with the Korea Biotechnology Research Institute Gene Bank (Daejeon, Korea) with accession number KCTC 11324BP.
- the neo 'gene that can resist G418 drugs by replacing the gene with Ampicillin resistance of the pBC1 vector (Invitrogen, USA) with a neomycin resistance gene is a pEGFP-N1 vector (Clontech, Obtained by amplifying a 1.9 kb PCR product (SEQ ID NO: 83) using a forward primer 5'-GCGGCCGCGCGCGTCAGGTGGCAC-3 '(SEQ ID NO: 81) and a reverse primer 5'-CGATCGGACGCTCAGTGGAACGAAAACTC-3' (SEQ ID NO: 82) Then, it was cloned into pGEM T-easy vector.
- the 1.9 kb neo gene cloned into the T-vector was digested with NotI and PvuI restriction enzymes (New England Biolabs (NEB), USA) to prepare an insertion site.
- the ampicillin-resistance gene region of the pBC1 vector was digested with NotI and PvuI restriction enzymes and removed to prepare a vector region.
- the two fragments and the vector sites thus prepared were ligated to construct a pBC1 vector into which a neo gene (neomycin-resistance gene) was inserted.
- erythropoietin in the vector and the goat (Goat) present in the vector
- the beta casein promoter site and the 3 'genomic DNA site were replaced with porcine alpha S 1 casein promoter nucleotide sequence (SEQ ID NO: 3) and 3'arm nucleotide sequence (SEQ ID NO: 5).
- WPRE woodchuck hepatitus virus post-transcriptional regulatory element
- PCR amplification of each of the hEPO and WPRE (PT-200, BIO-RAD, after 5 minutes of denaturation at 94, and then 35 cycles were performed: after denaturation at 94 °C for 30 seconds, primer binding for 30 seconds at 56 °C, HEPO was elongated at 72 ° C. for 2 minutes and 30 seconds, and WPRE was elongated for 30 seconds to obtain a product of 2.3 kb (SEQ ID NO: 69) and 0.6 kb (SEQ ID NO: 70), which was cloned into a pGEM-T vector to confirm the nucleotide sequence.
- the pGEM-T vector containing hEPO was cut into EcoRV and NotI (New England Biolabs (NEB), USA), and the pGEM-T vector containing WPRE was cut into EcoRV and NotI to ligated each fragment.
- Primer sequences used for amplification of hEPO and WPRE PCR are shown in the table below.
- the pBC1 vector was cut with BamHI and NotI to cut the lactic acid beta casein promoter and 3'genomic DAN, respectively, to prepare a vector, and hEPO + WPRE cloned into the pGEM-T vector was cut with BamHI and NotI to prepare an insert of 2.9 kb. .
- the prepared vector and insert were ligated to construct pBC1 + hEPO-WPRE.
- porcine alpha S1 promoter sequences 5.4kb (SEQ ID NO: 3) and 3'arm sequences 4.3kb (SEQ ID NO: 5) ) was cloned into each pGEM-T vector (Promega, USA).
- Primer sequences used for PCR amplification of the pig alpha S 1 casein promoter sequence and the 3'arm sequence are shown in the following table.
- GGATCC Two BamHI sites (GGATCC), which are present in the alpha s1 casein promoter sequence of pigs, were subjected to point mutations using an intron product Site Direct Mutagenesis using primers (SEQ ID NO: 60 to SEQ ID NO: 63).
- the pBC1 + hEPO-WPRE vector was cut with BamHI and treated with Alkaline Phosphatase (CIP) for 30 minutes to prepare the vector, and the pGEM-T vector containing the point mutatation pig alpha S 1 casein 5 'promoter DNA was cut with BamHI and cut into 5.5 kb. Insert (SEQ ID NO: 3) was prepared.
- Each fragment was ligated to clone the pBC1 pig ⁇ S1 casein 5 ′ + hEPO-WPRE vector.
- the pBC pig ⁇ S1 casein 5 '+ hEPO-WPRE vector was cut with NotI to prepare a vector by processing CIP for 30 minutes, and the pGEM-T vector containing 3'arm DNA was cut with NotI to insert an 4.3 kb insert (SEQ ID NO: 5). Ready.
- Each piece was ligated to construct a pBC1-pig ⁇ S1 casein + hEPO-WPRE vector.
- P ⁇ S1 casein of Figure 3 means a pig aS1 casein promoter nucleotide sequence (SEQ ID NO: 3), ⁇ S1-casein 3'genomic DNA means 3'arm nucleotide sequence (SEQ ID NO: 6).
- hEPO is a human EPO gene and WPRE is a woodchuck hepatitus virus post-transcriptional regulatory element gene.
- 2X ⁇ -globin insulator, and pBR322 are insulators and vector components derived from the pBC1 vector, and Neomycin is a neomycin resistance gene derived from the pEGFP-N1 vector (Clontech, USA).
- the pBC1-pig aS1 casein + hEPO-WPRE vector prepared by the above method was deposited at the Korea Biotechnology Research Institute Gene Bank (Daejeon, Korea) with Accession No. KCTC 11325BP.
- a swine alpha S 1 casein hEPO knock-in vector capable of confirming the correct gene introduction to a specific site using the TK gene selection method.
- Two pairs of primers (SEQ ID NOS: 74-76) were prepared, including up to the start codon and allowing the base sequence of the hEPO gene to be amplified after the start codon.
- Primary PCR amplification (PT-200, BIO-RAD) from human genomic DNA (preservative, pBC1-hEPO vector of Korean Patent No.
- Primer sequences used for hEPO PCR amplification are shown in the following table.
- primers of SEQ ID NO: 77 to SEQ ID NO: 80 were prepared and PCR 5.0 amplified from porcine genomic DNA by product 5.0kb (sequence). Nos. 4) and 4.9 kb (SEQ ID NO: 6) were cloned into the pGEM-T vector (pGEM-T-pig ⁇ S1 casein 5'arm, pGEM-T-pig ⁇ S1 casein 3'arm).
- Lox A neo-hEPO vector was cut with EcoR I restriction enzyme and 30 minutes treated with Alkaline phosphatase (New England Biolabs (NEB), USA) to insert poly A sequence for RNA stabilization towards Lox A neo-hEPO vector 3 '.
- 0.3 kb insert was prepared by cutting Bovine Growth Hormone (BGH) poly A derived from pcDNA3 vector (Invitrogen, USA) with EcoR I restriction enzyme. Each piece was ligation to construct a Lox A neo-hEPO-poly A vector.
- BGH Bovine Growth Hormone
- the Lox A neo-hEPO-poly A vector was inserted into the Lox A neo-hEPO-poly A vector 5 'to insert the Sal alpha, EcoR V restriction enzyme (New England Biolabs (NEB), USA). ), And the cloned pGEM-T-pig ⁇ S1 5'arm vector was cut with Sal I, EcoR V restriction enzyme to prepare an 5.0 kb insert (SEQ ID NO: 4). Each piece was ligation to construct a Lox A neo-hEPO-poly A-5'arm vector.
- Lox A neo-hEPO-poly A-5'arm vector was inserted into the 3'arm towards 3'arm by using the Lox A neo-hEPO-poly A-5'arm vector to Not I restriction enzyme (New England Biolabs (NEB), USA). ) And the vector was prepared by treating alkaline phosphatase for 30 minutes. The cloned pGEM-T-pig ⁇ S1 3′arm vector was cut with Not I restriction enzyme to prepare an insert (SEQ ID NO: 6) of 4.9 kb. Each piece was ligation to construct a Lox A neo-hEPO-poly A-5'arm-3'arm vector.
- HSV-tk Herpes simplex virus-thymidine kinase
- the pBS-TK vector (Gerard Karsenty's, Department of Genetics and Development, College of Physicians and Surgeons, Columbia University, New York, New York 10032) was cut with Not I restriction enzymes to insert a 2.3 kb insert (Herpes simplex virus-cymidine kinase). Gene coding portion). Each piece was ligation to construct a Lox A neo-hEPO-poly A-5'arm-3'arm-TK vector (Pig aS1 casein-hEPO knock-in vector).
- Pig ⁇ S1 casein 5 ′ arm of FIG. 4 means pig ⁇ S1 casein promoter (SEQ ID NO: 4), and Pig ⁇ S1 casein 3 ′ arm means 3′arm (SEQ ID NO: 6).
- hEPO is a human EPO gene
- poly A is a gene encoding poly A signal
- Neo cassette is a neomycin resistance gene
- positive selection gene PGK promoter is phosphoglycerate kinase (PGK) promoter
- TK Is a herpes simplex virus-thymidine kinase (HSV-tk) gene and is a negative selection gene and is derived from the pBS-TK vector.
- Pig aS1 casein-hEPO knock-in vector prepared by the above method was deposited in the Korea Biotechnology Research Institute Gene Bank (Daejeon, Korea) with accession number KCTC 11326BP.
- Mouse mammary cells (HC11, National Institute of Animal Science, Korea), mouse muscle cells (C2C12, ATCC, USA), human hepatocytes (HepG2, ATCC, USA), human kidney cells (Caki, ATCC, USA), human blood cells (U937 , ATCC, USA), rat brain cells (C6, ATCC, USA) and the like were cultured in the incubator under the following culture conditions.
- HC11-RPMI 1640 Gibco, USA
- 10% Fetal Bovine Serum FBS, HyClone, USA
- 1% penicillin streptomycin HyClone, USA
- insulin sigma, USA
- Cell lines grown about 80-90% were removed from the cell culture dish using trypsin (HyClone) and centrifuged at 1500 rpm for 5 minutes to remove supernatant. After counting the number of cells using a hemocytometer (Reichert, USA), cells were cultured in an incubator for 16-20 hours at 5 x 10 5 cells / dish in a 60 mm cell culture dish. Foreign genes were introduced using lipofectamine (invitrogen, USA) and introduced by introducing 4 ug of vectors prepared in Examples 2 and 3 per 60 mm cell culture dish.
- the HC 11 cell line was added 4 ug / ml of insulin (sigma, USA), 5 ug / ml of prolactin (sigma, USA) and 5 ug / ml of hydrocortisone (sigma, USA) 4 hours after the foreign gene.
- EPO expression was introduced into each cell line using a real-time PCR method with high sensitivity.
- Real-time PCR is a template of cDNA made using reverse transcriptase, and it is denatured using SYBR Green qPCR kit (FINNZYMES, Finland) and DNA engine Opticon 2 (BIO-RAD, USA) for 5 minutes at 94 ° C. The following 50 cycles were performed: after denaturation at 94 ° C. for 30 seconds, primer binding at 56 ° C. for 30 seconds, and fluorescence values after extension reaction at 72 ° C. for 60 seconds). For the correction of fluorescence value, Neo gene in the vector and beta actin gene in the cell were used. Results were analyzed using the GeneExMacro 3.0 (BIO-RAD) program. Primers used in PCR (SEQ ID NOs 84-91) are shown in the following table.
- Figure 5 shows the expression results of hEPO expression in mammary cells and tissue cells other than the mammary gland cells in which the pBC1-pig ⁇ S1 casein vector and the pBC1-pig ⁇ S1 casein + hEPO-WPRE vector were introduced.
- pBC1-hEPO-WPRE Cho-A Pharmaceutical, Korea Patent No. 10-0769291 vectors were introduced.
- the x axis represents each cell line
- the y axis represents the relative ratio of hEPO expressed in each cell line when the resultant values of pBC1-pig ⁇ S1 casein vector and pBC1 vector were set to 1.
- pPAC means the pBC1-pig ⁇ S1 casein vector of Example 2 and pPAC-hEPO means pBC1-pig ⁇ S1 casein + hEPO-WPRE of Example 3.
- pBC1 is a vector of invitrogen, which is made to have a goat promoter and expresses mammary gland-specific expression
- pBC1-hEPO means pBC1-hEPO-WPRE.
- hEPO was most expressed in mouse mammary cell HC11 cells and weakly expressed in human hepatocyte HepG2 and mouse muscle cell C2C12 cells, but not in other tissue cells.
- the desired protein can be produced in the mammary cell transformed with the vector of the present invention.
- the vector prepared in Example 3 was made linear using Sal 1 (NEB, R0138) and purified using Qiagen's QIAquick Gel Extraction kit (Q-28706) for injection buffer (10 mM Tris-HCl, 0.1 mM EDTA). , pH 7.4), and the final concentration was dispensed by 5ul at 2ng / ul and stored at -20 ° C.
- Hyperovulation was performed by injecting 5 IU of human chorionic gonadotropin (hCG, Intervet) 46 hours after injection of 5 IU of pregnant mare serum gonadotropin (PMSG; Intervet, Netherlands) in 8-week-old C57BL / 6 female rats (Orient Bio, South Korea). Induced. Light control was done every 12 hours (7 am to 7 pm), and PMSG was injected at 11 am by hCG at 9 am by intraperitoneal administration. After hCG injection, mating was performed with male rats of the same species to check vaginal plugs of female rats the next day to confirm that mating progressed normally.
- hCG human chorionic gonadotropin
- PMSG pregnant mare serum gonadotropin
- the isolated oviducts were separated into an M2 (Sigma, M7167) medium containing 0.1% hyaluronidase (Sigma, H3884) to separate the egg-oocyte complexes, and the bulge portion was then torn. After a while, only the fertilized eggs from which the oocytes were separated were collected, washed in clean M2 culture, and transferred to M16 (Sigma, M7292) culture, and cultured in a 37 ° C., 5% CO 2 incubator until the microinjection experiment.
- M2 Sigma, M7167
- H3884 0.1% hyaluronidase
- the recovered fertilized egg was placed.
- Microinjection of fertilized eggs was carried out in an OLYMPUS 1X71 TH4-200 inverted microscope (Narishige, Tokyo, Japan), a device for micromanipulation of fertilized eggs.
- the purified gene of 1) prepared beforehand is loaded into a femtotip injection pipette (Eppendorf) connected to a femtojet automatic injector (Eppendorf) using a microloader (Eppendorf, Hamburg, Germany).
- FIG. 6 shows PCR results for selecting mice transformed with the expression vector pBC1-pig alpha S1 casein + hEPO-WPRE vector of Example 3.
- FIG. EPO-WPRE of Figure 6 is the result for the EPO-WPRE gene region
- WPRE-3'arm is the result for the EPO-alpha S1 3'arm gene region.
- M is a size marker
- V is a pBC1-pig-alpha S1 casein-EPO-WPRE vector
- N normal mouse genomic DNA for negative control, and the number represents each individual.
- mice in which the pig alpha S 1 casein gene introduction was confirmed the females were bred with normal males after 6 weeks of adult maturity to produce pups, and then introduced the foreign genes to the pups in the same manner as in 5). Confirmed.
- FIG. EPO-WPRE of Figure 7 is the result for the EPO-WPRE gene region
- WPRE-alpha S1 is the result for the EPO-alpha S1 3'arm gene region
- M is the size marker
- V is the pBC1-pig-alpha S1 casein-EPO-WPRE vector
- N normal mouse genomic DNA for negative control
- 1-1 to 1-6 are litters of transgenic mice. do.
- mice were isolated from the rats after 7 days of lactation, and 2 hours later, milk was collected with oxytocin 10 IU intraperitoneally and massaging the mammary gland. Western blot assay was performed using milk. The 12% SDS-PAGE gel was transferred to PVDF membrane (millipore, USA) and incubated with 5% Skim milk blocking solution. Anti-human EPO antibody (1: 1,000, hEPO anti-rabbit antibody, R & D systems Cat.No. AB-286-NA, Lot No. HX01, USA) was added to the membrane according to the manufacturer's protocol for 1 hour at room temperature. Incubated.
- TBST buffer tris buffered saline buffer, 0.01% tween-20
- peroxidase labeled anti rabbit antibody (1: 3,000, peroxidase labeled anti-rabbit antibody, GE healthcare, Cat. NA9340V, Lot No. 348424, UK) was added and incubated at room temperature for 1 hour, then washed with TBST buffer and exposed to film.
- FIG. Figure 8 shows the results of Wessblot assay using the milk of the transformed mother.
- 1-4 of FIG. 8 shows EPO standard (calbiochem, USA), and 5-6 shows a sample.
- ELISA Enzyme-linked immunosorbent assay
- the swine alpha 1 casein gene is available for the production of swine alpha 1 casein, and since the swine alpha 1 casein gene promoter promotes mammary specific expression of the target protein, the promoter of the present invention and the expression vector using the same Animals transformed by the high concentration of the protein to be secreted in milk can be usefully used in the production of useful proteins having a medicinal value.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Environmental Sciences (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Animal Behavior & Ethology (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Cell Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
서열번호 | 염기서열 분석용 프라이머 |
20 | 5'-TAACGAATCCAACTAGGAACC-3' |
21 | 5'-TCCTTCTCCAACCCTATATTC-3' |
22 | 5'-TGAGAGGGGAATAGAAAGAAC-3' |
23 | 5'-TATCAATAGGTCTCAGAAGATC-3' |
24 | 5'-TAGACTTCGAGTTTGGAGGG-3' |
25 | 5'-TATAAGGCACAAATGAGCCCTT-3' |
26 | 5'-AAATGCTCAACATCCCTGATTA-3' |
27 | 5'-TATTCCGTGTTCATGGATTGG-3' |
28 | 5'-AAGTATTCTCCACTGCCTTAC-3' |
29 | 5'-TGTGAGTATGGTAGAGAATTT-3' |
30 | 5'-CTATTGTGAATAGAGCTGCAAT-3' |
31 | 5'-GTGTGAGAGTGTGTACCAGTT-3' |
32 | 5'-TGTTCCCTTGTGATATATAGC-3' |
33 | 5'-CTTGTTCCCACAGTTCAAATG-3' |
34 | 5'-TAGATACCTCCACCAAGAGC-3' |
35 | 5'-TTCTCAGGTTTCCTGAGGTG-3' |
36 | 5'-GTGCACATTTACATACTGATAG-3' |
37 | 5'-ATCATCAATGAACTGAACAGGGT-3' |
38 | 5'-TTGAGACCTAAGTCACAGCTA-3' |
39 | 5'-TCCATAATAATTTATGTCAAGGG-3' |
40 | 5'-TAAGGCAAAATGTGCATGAGTG-3' |
Claims (25)
- 프로모터, 및 3' UTR 부위를 포함하는 서열번호 1의 염기서열을 갖는 돼지 알파에스 1 카제인 유전자.
- 서열번호 2의 염기서열을 포함하는 돼지 알파에스 1 카제인 유전자 프로모터.
- 서열번호 2의 염기서열, 서열번호 3의 염기서열, 및 서열번호 4의 염기서열 중에서 선택된 하나 이상의 염기서열을 포함하는 발현 벡터.
- 제3항에 있어서, 상기 벡터는 서열번호 5 또는 서열번호 6 중에서 선택된 하나 이상의 염기서열을 추가로 갖는 것인 발현벡터.
- 제3항에 있어서, 상기 벡터는 선택적 표지 유전자, 인슐레이터, 및 WPRE(woodchuck hepatitus virus posttranscriptional regulatory element) 중에서 선택된 하나 이상이 추가된 것인 발현벡터.
- 제5항에 있어서, 상기 벡터는 도 2의 개열지도를 갖는 것인 발현 벡터.
- 제6항에 있어서, 상기 벡터는 기탁번호 KCTC 11324BP로 기탁된 pBC1-pig αS1 casein인 발현 벡터.
- 제3항 내지 제5항 중 어느 한 항에 있어서, 프로모터 염기서열의 3' 쪽으로 목적단백질을 암호화하는 염기서열을 추가로 갖는 발현 벡터.
- 제8항에 있어서, 상기 목적단백질은 인간EPO(erythropoietin)인 발현 벡터.
- 제9항에 있어서, 상기 벡터는 도 3의 개열지도를 갖는 것인 발현 벡터.
- 제10항에 있어서, 상기 벡터는 기탁번호 KCTC 11325BP로 기탁된 pBC1-pig αS1 casein+hEPO-WPRE인 발현 벡터.
- 제4항에 있어서, 상기 발현벡터는 낙인벡터(knock-in vector)인 발현벡터.
- 제12항에 있어서, 상기 낙인벡터는 선별유전자가 추가된 것인 발현 벡터.
- 제13항에 있어서, 상기 낙인벡터는 도 4의 개열지도를 갖는 것인 발현 벡터.
- 제14항에 있어서, 상기 낙인벡터는 기탁번호 KCTC 11326BP로 기탁된 Pig αS1 casein-hEPO knock in인 발현 벡터.
- 제3항 내지 제5항 중 어느 한 항의 발현 벡터를 도입시켜 형질전환시킨 동물의 체세포.
- 제3항 내지 제5항 중 어느 한 항의 발현 벡터가 주입된 동물 수정란.
- 제17항에 있어서, 상기 주입은 미세주입법에 의한 것인 동물 수정란.
- 제17항의 동물 수정란을 이식시켜 얻은 형질전환동물.
- 제19항에 있어서, 상기 형질전환동물은 돼지, 생쥐, 소, 양, 및 염소 중에서 선택된 하나인 형질전환동물.
- 제17항의 동물수정란을 대리모의 난관 내에 이식한 후, 대리모로부터 형질전환동물을 얻고, 상기 형질전환동물의 유즙으로부터 목적단백질을 제조하는 제조방법.
- 제3항 내지 제5항 중 어느 한 항의 발현 벡터를 도입시켜 형질전환시킨 동물의 체세포를 탈핵된 난자에 핵이식하여 만든 동물 수정란.
- 제22항의 수정란을 이식시켜 얻은 형질전환동물.
- 제23항에 있어서, 상기 형질전환동물은 돼지, 생쥐, 소, 양, 및 염소 중에서 선택된 하나인 형질전환동물.
- 제3항 내지 제5항 중 어느 한 항의 발현 벡터를 도입시켜 형질전환된 동물의 체세포를 탈핵된 난자에 핵이식하여 만든 동물 수정란을 대리모 동물에 이식하고, 상기 대리모 동물로부터 형질전환동물을 얻고, 상기 형질전환동물의 유즙으로부터 목적단백질을 생산하는 단계를 포함하는 단백질의 제조방법.
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2729625A CA2729625C (en) | 2008-06-30 | 2009-06-29 | Gene of porcine alpha-s1-casein, a promoter of the same and the use thereof |
CN200980126110XA CN102124109B (zh) | 2008-06-30 | 2009-06-29 | 猪α-S1-酪蛋白基因,其启动子及其用途 |
AU2009266603A AU2009266603B2 (en) | 2008-06-30 | 2009-06-29 | Gene of porcine alpha-s1 casein, a promoter of the same and use thereof |
JP2011516140A JP5507555B2 (ja) | 2008-06-30 | 2009-06-29 | 豚のαS1カゼイン遺伝子、そのプロモーター、及びその用途 |
EP09773696.1A EP2305814B1 (en) | 2008-06-30 | 2009-06-29 | Gene of porcine alpha-s1 casein, a promoter of the same and use thereof |
US12/737,319 US9738694B2 (en) | 2008-06-30 | 2009-06-29 | Gene of porcine alpha-s1 casein, a promoter of the same and use thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2008-0062765 | 2008-06-30 | ||
KR20080062765 | 2008-06-30 |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2010002160A2 true WO2010002160A2 (ko) | 2010-01-07 |
WO2010002160A9 WO2010002160A9 (ko) | 2010-05-06 |
WO2010002160A3 WO2010002160A3 (ko) | 2010-07-01 |
Family
ID=41466443
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2009/003516 WO2010002160A2 (ko) | 2008-06-30 | 2009-06-29 | 돼지의 알파에스 1 카제인 유전자, 그 프로모터 및 그의 용도 |
Country Status (8)
Country | Link |
---|---|
US (1) | US9738694B2 (ko) |
EP (1) | EP2305814B1 (ko) |
JP (1) | JP5507555B2 (ko) |
KR (1) | KR101033818B1 (ko) |
CN (1) | CN102124109B (ko) |
AU (1) | AU2009266603B2 (ko) |
CA (1) | CA2729625C (ko) |
WO (1) | WO2010002160A2 (ko) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8420388B2 (en) | 2008-06-30 | 2013-04-16 | Cho-A Pharm. Co., Ltd. | Gene of porcine beta casein, a promoter of the same and the use thereof |
US9458205B2 (en) | 2011-11-16 | 2016-10-04 | Sangamo Biosciences, Inc. | Modified DNA-binding proteins and uses thereof |
CN102653773B (zh) * | 2012-04-26 | 2015-01-14 | 天津农学院 | 牛乳腺特异性表达载体pBC-αs1及制备方法 |
KR101938956B1 (ko) | 2016-05-31 | 2019-01-15 | 제주대학교 산학협력단 | 신경세포 특이적으로 발현하는 돼지 Thy1 유전자 프로모터 |
KR101928659B1 (ko) | 2017-06-19 | 2018-12-13 | 서울대학교병원 | Dna 변형 유도 단백질 복합체 및 이를 암호화하는 유전자를 포함하는 재조합 벡터 |
CN110257392A (zh) * | 2019-06-28 | 2019-09-20 | 西安医学院 | 转录后水平低氧调控基因、应用及其调控方法 |
CA3191387A1 (en) | 2020-09-30 | 2022-04-07 | Nobell Foods, Inc. | Recombinant milk proteins and food compositions comprising the same |
US10947552B1 (en) | 2020-09-30 | 2021-03-16 | Alpine Roads, Inc. | Recombinant fusion proteins for producing milk proteins in plants |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100232640B1 (ko) | 1997-06-03 | 1999-12-01 | 박호군 | 에리트로포이에틴 (epo)을 생산하는 세포주, 그의 제조방법 및 이를 이용한 epo의 제조방법 |
KR100358754B1 (ko) | 2000-02-14 | 2002-11-07 | 대한민국 | 인간의 조혈촉진제 생산을 위한 형질전환 돼지를 생산하는방법 및 그 형질전환 돼지 |
KR100434729B1 (ko) | 1998-03-18 | 2004-11-03 | 주식회사 엘지생명과학 | 천연 추출물을 첨가하여 중국햄스터 난소 유래세포에서 에리스로포이에틴의 생산 증대방법 |
KR100769291B1 (ko) | 2006-02-13 | 2007-10-24 | 조아제약주식회사 | 유선 특이적 인간 에리트로포이에틴 발현 벡터, 이를이용한 형질전환 동물 및 이를 이용한 인간에리트로포이에틴의 생산 방법 |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0279582A3 (en) | 1987-02-17 | 1989-10-18 | Pharming B.V. | Dna sequences to target proteins to the mammary gland for efficient secretion |
US4873316A (en) | 1987-06-23 | 1989-10-10 | Biogen, Inc. | Isolation of exogenous recombinant proteins from the milk of transgenic mammals |
EP0688358A4 (en) | 1993-03-12 | 1997-10-01 | Univ Creighton | IMPROVED VECTORS FOR GENTHERAPY |
US5610053A (en) | 1993-04-07 | 1997-03-11 | The United States Of America As Represented By The Department Of Health And Human Services | DNA sequence which acts as a chromatin insulator element to protect expressed genes from cis-acting regulatory sequences in mammalian cells |
US5959171A (en) | 1994-08-17 | 1999-09-28 | Pharming B.V. | Method for the production of biologically active polypeptides in a mammal's |
JPH09298981A (ja) * | 1996-05-16 | 1997-11-25 | Y S New Technol Kenkyusho:Kk | トランスジェニックブタ |
JPH1084981A (ja) * | 1996-07-26 | 1998-04-07 | Y S New Technol Kenkyusho:Kk | 乳腺発現用ベクター |
US6136597A (en) | 1997-09-18 | 2000-10-24 | The Salk Institute For Biological Studies | RNA export element |
US6436707B1 (en) | 1998-03-27 | 2002-08-20 | Lexicon Genetics Incorporated | Vectors for gene mutagenesis and gene discovery |
EP1088084B1 (en) | 1998-06-15 | 2006-09-13 | GTC Biotherapeutics, Inc. | Erythropoietin analog-human serum albumin fusion protein |
JP2001197846A (ja) * | 2000-01-18 | 2001-07-24 | Ys New Technology Kenkyusho:Kk | 免疫寛容動物の作製方法 |
DE122011000002I1 (de) | 2000-01-31 | 2011-05-05 | Pharming Intellectual Pty Bv | Humaner c1 inhibitor hergestellt in der milch transgener säugetiere |
WO2002077161A2 (en) * | 2001-03-12 | 2002-10-03 | Progenetics Llc | Production of high levels of trangenic factor ix without gene rescue, and its therapeutic uses |
CN1283785C (zh) | 2002-05-20 | 2006-11-08 | 上海杰隆生物工程股份有限公司 | 利用转基因动物乳腺生产人促红细胞生成素的方法 |
CU23102A1 (es) * | 2002-10-21 | 2005-12-20 | Ct Ingenieria Genetica Biotech | Método para la producción de proteínas recombinantes en la glándula mamaria de mamíferos no transgénicos |
DE60318882D1 (de) | 2002-11-04 | 2008-03-13 | Cho A Pharm Co Ltd | Uroplakin-ii-promotor aus schwein und verfahren zur herstellung nützlicher proteine unter verwendung des promotors |
KR100552634B1 (ko) | 2002-11-04 | 2006-02-20 | 조아제약주식회사 | 돼지의 유로플라킨 ⅱ 유전자의 프로모터 및 이를 이용한유용단백질의 생산 방법 |
KR20040101793A (ko) | 2003-05-27 | 2004-12-03 | 재단법인서울대학교산학협력재단 | 사람 에리트로포이에틴을 생산하는 형질전환 복제소 및이의 생산 방법 |
JP2005160359A (ja) * | 2003-12-01 | 2005-06-23 | Rikogaku Shinkokai | Sineの挿入多型を指標とした鯨種判別方法 |
US7667089B2 (en) * | 2004-04-09 | 2010-02-23 | National Chung Hsing University | Transgenic mammal secreting B-domain deleted human FVII in its milk |
EA016039B1 (ru) * | 2005-05-02 | 2012-01-30 | Милеутис Лтд. | Способы ухода за лактирующими животными и фармацевтические композиции, используемые для их осуществления |
US7902352B2 (en) | 2005-05-06 | 2011-03-08 | Medtronic, Inc. | Isolated nucleic acid duplex for reducing huntington gene expression |
EP3437473A1 (en) * | 2006-05-04 | 2019-02-06 | Wayne State University | Restoration of visual responses by in vivo delivery of rhodopsin nucleic acids |
GB2458419B (en) * | 2006-12-20 | 2011-02-16 | Ji-Chang You | Vector for expressing NC protein of HIV and method for producing NC protein using the same |
JP2010535496A (ja) | 2007-08-08 | 2010-11-25 | チョ−エー・ファーム・カンパニー・リミテッド | 乳腺特異的ヒトエリトロポエチン発現ベクター、これを用いた形質転換動物及びこれを用いたヒトエリトロポエチンの産生方法 |
US8420388B2 (en) | 2008-06-30 | 2013-04-16 | Cho-A Pharm. Co., Ltd. | Gene of porcine beta casein, a promoter of the same and the use thereof |
-
2009
- 2009-06-29 US US12/737,319 patent/US9738694B2/en active Active
- 2009-06-29 JP JP2011516140A patent/JP5507555B2/ja active Active
- 2009-06-29 EP EP09773696.1A patent/EP2305814B1/en active Active
- 2009-06-29 KR KR1020090058189A patent/KR101033818B1/ko active IP Right Grant
- 2009-06-29 CA CA2729625A patent/CA2729625C/en active Active
- 2009-06-29 AU AU2009266603A patent/AU2009266603B2/en active Active
- 2009-06-29 WO PCT/KR2009/003516 patent/WO2010002160A2/ko active Application Filing
- 2009-06-29 CN CN200980126110XA patent/CN102124109B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100232640B1 (ko) | 1997-06-03 | 1999-12-01 | 박호군 | 에리트로포이에틴 (epo)을 생산하는 세포주, 그의 제조방법 및 이를 이용한 epo의 제조방법 |
KR100434729B1 (ko) | 1998-03-18 | 2004-11-03 | 주식회사 엘지생명과학 | 천연 추출물을 첨가하여 중국햄스터 난소 유래세포에서 에리스로포이에틴의 생산 증대방법 |
KR100358754B1 (ko) | 2000-02-14 | 2002-11-07 | 대한민국 | 인간의 조혈촉진제 생산을 위한 형질전환 돼지를 생산하는방법 및 그 형질전환 돼지 |
KR100769291B1 (ko) | 2006-02-13 | 2007-10-24 | 조아제약주식회사 | 유선 특이적 인간 에리트로포이에틴 발현 벡터, 이를이용한 형질전환 동물 및 이를 이용한 인간에리트로포이에틴의 생산 방법 |
Non-Patent Citations (4)
Title |
---|
A. GOKANA; J.J. WINCHENN; A. BEN-GHANEM; A. AHADED; J.P. CARTRON; P. LAMBIN: "Chromatographic separation of recombinant human erythropoietin isoforms", JOURNAL OF CHROMATOGRAPHY, vol. 791, 1997, pages 109 - 118 |
FREDERICK M. AUSUBEL ET AL.: "Current Protocols in Molecular Biology", vol. 1, 2, 3, 1994, JOHN WILEY & SONS, INC. |
SAMBROOK ET AL.: "Molecular Cloning, A Laboratory Manual", 2001, COLD SPRING HARBOR LABORATORY PRESS |
See also references of EP2305814A4 |
Also Published As
Publication number | Publication date |
---|---|
CN102124109A (zh) | 2011-07-13 |
JP2011526495A (ja) | 2011-10-13 |
JP5507555B2 (ja) | 2014-05-28 |
CA2729625A1 (en) | 2010-01-07 |
US20110239314A1 (en) | 2011-09-29 |
EP2305814A4 (en) | 2011-12-28 |
AU2009266603A1 (en) | 2010-01-07 |
WO2010002160A9 (ko) | 2010-05-06 |
KR101033818B1 (ko) | 2011-05-13 |
CN102124109B (zh) | 2013-10-16 |
CA2729625C (en) | 2016-02-02 |
KR20100003223A (ko) | 2010-01-07 |
EP2305814B1 (en) | 2015-08-05 |
AU2009266603B2 (en) | 2013-01-24 |
EP2305814A2 (en) | 2011-04-06 |
US9738694B2 (en) | 2017-08-22 |
WO2010002160A3 (ko) | 2010-07-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2010002160A2 (ko) | 돼지의 알파에스 1 카제인 유전자, 그 프로모터 및 그의 용도 | |
JP3571337B2 (ja) | 遺伝子標的現象による同型遺伝子接合 | |
JP2007503838A (ja) | トランスジェニック動物の乳汁中での融合タンパク質の産生方法 | |
Feng et al. | Production of transgenic dairy goat expressing human α-lactalbumin by somatic cell nuclear transfer | |
Montoliu | Gene transfer strategies in animal transgenesis | |
US20090187999A1 (en) | Process for Producing Exogenous Protein in the Milk of Transgenic Mammals and a Process For Purifying Proteins Therefrom | |
CA2237392A1 (en) | Production of somatic mosaicism in mammals using a recombinatorial substrate | |
KR101033819B1 (ko) | 돼지의 베타 카제인 유전자, 그 프로모터 및 그의 용도 | |
US7511126B2 (en) | Position-independent and tissue specific expression of a transgene in milk of transgenic animals | |
WO2014178485A1 (ko) | Cmp-아세틸뉴라미닌산 히드록실라아제 타겟팅 벡터, 그 벡터가 도입된 이종간 이식용 형질전환 동물 및 그 제조방법 | |
WO2017082667A1 (ko) | HO-1 유전자 및 TNFR1-Fc 유전자를 동시에 발현하며 GGTA1 유전자가 넉아웃된 형질전환 돼지 및 이의 용도 | |
KR101636885B1 (ko) | 소 베타-카제인과 융합된 바이오 신약용 단백질 생산을 위한 넉-인 방법 | |
WO2011132990A2 (ko) | Pepck 과발현 형질전환 복제 개과 동물 및 이의 생산방법 | |
US20240074415A1 (en) | Livestock animals with improved growth performance | |
KR101918607B1 (ko) | 소 락토페린 발현을 위한 넉-인 벡터 및 이를 이용한 소 수정란에서 넉-인 방법 | |
KR20100039620A (ko) | 돼지 베타-카제인 게놈 DNA를 이용하여human basic FGF를 생산하기 위한 넉-인 벡터가 도입된 형질전환 돼지 체세포 제작 방법 | |
Devinoy et al. | Analysis of the efficiency of the rabbit whey acidic protein gene 5′ flanking region in controlling the expression of homologous and heterologous linked genes | |
KR101628701B1 (ko) | 소 넉-인용 벡터 및 그의 용도 | |
Luckow et al. | Microinjection of Cre recombinase protein into zygotes enables specific deletion of two eukaryotic selection cassettes and enhances the expression of a DsRed2 reporter gene in Ccr2/Ccr5 double‐deficient mice | |
WO2020091472A1 (ko) | 근육 특이적 퍼옥시좀 증식체 활성화 수용체 델타(PPARδ) 과발현 형질전환 개 생산 | |
염수영 | Generation and analysis of transgenic cattle with germline transmission via transposon | |
EP1535512A1 (en) | DISEASE MODEL ANIMAL CARRYING FOREIGN PPARa GENE TRANSFERRED THEREINTO AND USE THEREOF | |
Lee et al. | Knock-in of Enhanced Green Fluorescent Protein or/and Human Fibroblast Growth Factor 2 Gene into β-Casein Gene Locus in the Porcine Fibroblasts to Produce Therapeutic Protein | |
KR100952960B1 (ko) | 돼지 β-카제인 게놈 DNA를 이용하여 생리활성물질을생산하기 위한 넉-인 벡터 및 이를 이용하여생리활성물질을 생산하는 방법 | |
GB2331752A (en) | Vectors and YACs comprising an IRES |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200980126110.X Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09773696 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 4940/KOLNP/2010 Country of ref document: IN |
|
ENP | Entry into the national phase |
Ref document number: 2011516140 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2729625 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009773696 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009266603 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2009266603 Country of ref document: AU Date of ref document: 20090629 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12737319 Country of ref document: US |